A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

To be part of this study, you must be an adult aged 18 or over and have a confirmed diagnosis of multiple myeloma following specific medical guidelines. You should have recently started a particular multiple myeloma treatment called teclistamab, within the last 8 weeks, and plan to continue it for the next 12 months. Everyone joining the study must also provide written agreement (informed consent).

There are also some reasons why you might not be able to join. For example, if your multiple myeloma hasn't shown at least a small improvement from your current teclistamab treatment within the first 8 weeks, or if you have a current serious infection. You also won't be able to join if you've already had more than one serious infection in the last three months, or if you've recently received similar blood products or certain vaccines that interact with the study medicine. The study will also check specific blood test results related to your immune system.

If you decide to join this study, your participation will last for up to 14 months, which includes an initial checking period of up to 8 weeks. During the study, you will need to visit the study clinic either 15 times (if you receive the study medicine every 4 weeks) or 19 times (if you receive it every 3 weeks). These visits are important so the study team can monitor your health, give you the study medicine (IGI), and check how you are responding to it. You will also have various tests and assessments during these visits.